Skip to content

VeClose Five Year Follow-Up Extension Study

Follow-up of Patients Treated in VeClose Study (Five Years)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03455699
Enrollment
114
Registered
2018-03-06
Start date
2016-07-31
Completion date
2019-01-31
Last updated
2019-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Great Saphenous Vein (GSV) With Venous Reflux Disease

Keywords

GSV

Brief summary

The VeClose Five Year Follow-up Extension Study will seek to gain additional follow-up data from the patients enrolled in the VeClose study (NCT01807585).

Detailed description

The VeClose Five Year Follow-up Extension Study will continue to assess the safety and efficacy of the VenaSeal Closure System for the long term effect on closure of the great saphenous vein by conducting a follow-up visit at five years post index procedure/enrollment in the VeClose study.

Interventions

Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.

Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.

Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.

Sponsors

Medtronic Endovascular
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Enrolled in the VeClose study. 2. Able and willing to complete the required 5 year study visit including Duplex ultrasound exam. 3. Able and willing to provide written informed consent prior to study specific data collection.

Exclusion criteria

1\. Withdrew consent from the VeClose study.

Design outcomes

Primary

MeasureTime frameDescription
Complete Closure of the Target Vein at 5 years after index treatment in the VeClose study (NCT01807585).5 yearsComplete closure is defined as Doppler ultrasound examination showing closure along entire treated target vein segment with no discrete segments of patency exceeding 5cm.

Secondary

MeasureTime frameDescription
Aberdeen Varicose Vein Questionnaire (AVVQ)5 yearsChange in Aberdeen Varicose Vein Questionnaire (AVVQ) at 5 years as compared to baseline data from the VeClose study (NCT01807585). AVVQ is a disease-specific 13-item questionnaire used to assess the impact of varicose veins on the quality of life, such as pain caused by varicose veins, and need to take painkilling tablets for varicose veins as well as assessing the presence of signs/symptoms such as ankle swelling, purple discoloration and rash/eczema. The total score of AVVQ is the sum of all questions for each leg. Scores range from 0 (no disease) to 100 (maximal disease). High scores indicate worse outcomes and 0 is the best possible outcome.
Quality of Life survey (EQ-5D)5 yearsChange in Quality of Life survey (EQ-5D) at 5 years as compared to baseline data from the VeClose study (NCT01807585). EQ-5D is a short generic quality of life survey that is commonly used outside of the United States for health technology assessments. The health state today question provides an overall assessment along a 20-cm visual analog scale (VAS) with a range from 0 (worst imaginable health state) to 100 (best imaginable health state).
CEAP classification (clinical, etiology, assessment and pathophysiology)5 yearsStandardized measure of the degree of venous insufficiency and secondary manifestations of venous disease as measured by the treating physician.
Venous Clinical Severity Score (VCSS)5 yearsChange in Venous Clinical Severity Score (VCSS) at 5 years as compared to baseline data from the VeClose study (NCT01807585). The VCSS is an Investigator assessment of the severity of venous reflux disease, assessing signs and symptoms such as pain, varicose veins, venous edema, skin pigmentation, induration and inflammation. The VCSS score is the sum of responses to 10 questions. Each question has a total possible of 3 points, which are then added for each question. The overall VCSS scores can therefore range from 0 (no venous disease) to 30 (severe venous disease). High scores indicate worse outcomes and 0 is the best possible outcome.
Adverse events (AE) related to the target GSV5 yearsAEs related to the GSV will be tabulated and reporting using the MedDRA dictionary, version 16.1.
Adjunctive procedures performed on the study limb5 yearsDetails of adjunctive procedures performed on the study limb will be captured on Case Report Forms (CRFs)
Satisfaction with Treatment5 yearsSatisfaction with Treatment assessment consists of a brief 2-question patient survey rating satisfaction with treatment provided and whether the subject would undergo the assigned treatment again. The number (percent) of subjects on each level of satisfaction are summarized (Very satisfied, Somewhat satisfied, Somewhat dissatisfied, Very dissatisfied). The number (percent) of subjects for the second satisfaction question, would undergo treatment again were also summarized by response (Definitely have again, Might have again, Not have again).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026